XELSTRYM
ADHD
ApprovedActive
Key Facts
About Noven Pharmaceuticals
Noven Pharmaceuticals is a U.S.-based, commercial-stage specialty pharma company with a core competency in transdermal patch technology. Founded in 1989, the company has a portfolio of marketed products for ADHD, schizophrenia, and menopausal hormone therapy, leveraging its fully integrated capabilities from R&D to sales. As a wholly-owned subsidiary of Hisamitsu, Noven benefits from deep transdermal expertise and manufacturing scale while focusing on niche CNS and women's health markets. Its strategy combines internal development with strategic partnerships to expand its product offerings.
View full company profileTherapeutic Areas
Other ADHD Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Program | Curemark | Preclinical |
| NRCT-101SR | Neurocentria | Phase 2b/3 |
| DAYTRANA | Noven Pharmaceuticals | Approved |
| QELBREE (viloxazine ER) | Supernus Pharmaceuticals | Approved |
| JORNAY PM | Collegium Pharmaceutical | Marketed |
| AZSTARYS | Collegium Pharmaceutical | Acquisition Pending |
| CTx-1301 | Cingulate | Phase 3 |
| CTx-1302 | Cingulate | Phase 3 |